VWF and COVID-19: Therefore, based on the results of previous studies, a consensus by the International COVID-19 Thrombosis Biomarkers Colloquium concluded that vWF and the ratio of vWF antigen to ADAMTS13 have benefits for determining the prognosis of thromboembolism in COVID-19 but are less optimal for predicting the risk of thrombosis [60].